文献速递免疫规划传染病防控与疫情报告

COVID-19大流行对肯尼亚基利菲疫苗覆盖率的影响:一项回顾性队列研究

The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study.
PubMed 文献 · Vaccine · 2022-11-01

研究在肯尼亚基利菲县基利菲健康与人口监测系统(KHDSS)内于2021年4月至6月开展疫苗覆盖调查,简单随机抽样纳入1500名6周至59月龄儿童,最终分析1341名参与者。按成为疫苗接种年龄合格的时间分为大流行前、大流行第一年和大流行第二年三个回顾性队列,采用Cox回归生存分析评估时间期与接种率的关系。结果显示,调整已知疫苗接种决定因素后,COVID-19大流行未对KHDSS内接种率产生不利影响。

要点

  • 五价疫苗第三剂(Pentavalent-3)在年龄合格后1个月内接种率:大流行第一年与基线无显著差异(aHR 1.03,95%CI 0.90-1.18),第二年显著更高(aHR 1.33,95%CI 1.07-1.65)。
  • 麻疹疫苗第一剂(MCV-1)在年龄合格后3个月内接种率:大流行第一年与基线无显著差异(aHR 1.04,95%CI 0.88-1.21),第二年较基线高35%(95%CI 1.11-1.64)。
  • 调整已知疫苗接种决定因素后,COVID-19大流行未对KHDSS内接种率产生不利影响。

核心结论

  • 调整已知疫苗接种决定因素后,COVID-19大流行未对KHDSS内疫苗接种率产生不利影响。

研究设计与样本

  • 2021年4月至6月在肯尼亚基利菲县基利菲健康与人口监测系统(KHDSS)内开展疫苗覆盖调查,采用简单随机抽样识别1500名6周至59月龄儿童。
  • 参与者按成为疫苗接种年龄合格的时间分为三个回顾性队列:大流行前、大流行第一年或大流行第二年。
  • 采用Cox回归生存分析评估成为疫苗接种年龄合格的时间期与接种率之间的关联。
  • 最终共有1341名参与者纳入调查分析。

主要发现

  • 五价疫苗第三剂(Pentavalent-3)在年龄合格后1个月内接种率:与大流行前基线相比,大流行第一年无显著差异(aHR 1.03,95%CI 0.90-1.18),大流行第二年显著更高(aHR 1.33,95%CI 1.07-1.65)。
  • 麻疹疫苗第一剂(MCV-1)在年龄合格后3个月内接种率:与大流行前基线相比,大流行第一年无显著差异(aHR 1.04,95%CI 0.88-1.21),大流行第二年高35%(95%CI 1.11-1.64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic caused unprecedented disruption in health service delivery, globally. This study sought to provide evidence on the impact of the pandemic on vaccine coverage in Kilifi County, Kenya. We conducted a vaccine coverage survey between April and June 2021 within the Kilifi Health and Demographic Surveillance System (KHDSS). Simple random sampling was used to identify 1500 children aged 6 weeks-59 months. Participants were grouped into three retrospective cohorts based on when they became age-eligible for vaccination: before the pandemic, during the first year, or during the second year of the pandemic. Survival analysis with Cox regression was used to evaluate the association between the time-period at which participants became age-eligible for vaccination and the rate of vaccination within a month of age-eligibility for the third dose of pentavalent vaccine (Pentavalent-3) and within three months of age-eligibility for the first dose of Measles vaccine (MCV-1). A total of 1,341 participants were included in the survey. Compared to the pre-COVID-19 baseline period, the rate of vaccination within a month of age-eligibility for Pentavalent-3 was not significantly different in the first year of the pandemic (adjusted hazard ratio [aHR] 1.03, 95 % confidence interval [CI] 0.90-1.18) and was significantly higher during the second year of the pandemic (aHR 1.33, 95 % CI 1.07-1.65). The rate of vaccination with MCV-1 within three months of age-eligibility was not significantly different among those age-eligible for vaccination during the first year of the pandemic (aHR 1.04, 95 % CI 0.88-1.21) and was 35 % higher during the second year of the pandemic (95 % CI 1.11-1.64), compared to those age-eligible pre-COVID-19. After adjusting for known determinants of vaccination, the COVID-19 pandemic did not adversely affect the rate of vaccination within the KHDSS.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lucinde RK, Karia B, Ouma N, et al. The impact of the COVID-19 pandemic on vaccine coverage in Kilifi, Kenya: A retrospective cohort study. Vaccine. 2022. PMID: 36543684. doi:10.1016/j.vaccine.2022.10.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。